Insider Selling: Artivion (NYSE:AORT) Insider Sells $172,767.94 in Stock

Artivion, Inc. (NYSE:AORT) insider John Davis sold 4,573 shares of the firm’s stock in a transaction dated Tuesday, March 3rd. The shares were sold at an average price of $37.78, for a total value of $172,767.94. Following the completion of the transaction, the insider owned 230,794 shares of the company’s stock, valued at $8,719,397.32. The trade was a 1.94% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Artivion Price Performance

NYSE:AORT opened at $37.18 on Friday. Artivion, Inc. has a 52-week low of $21.97 and a 52-week high of $48.25. The company has a market cap of $1.78 billion, a P/E ratio of 185.91 and a beta of 1.60. The company has a debt-to-equity ratio of 0.49, a quick ratio of 2.62 and a current ratio of 3.53. The stock’s 50-day simple moving average is $41.06 and its 200 day simple moving average is $42.84.

Artivion (NYSE:AORT) last issued its quarterly earnings results on Thursday, February 12th. The company reported $0.17 EPS for the quarter, beating the consensus estimate of $0.14 by $0.03. The firm had revenue of $118.30 million during the quarter, compared to analysts’ expectations of $116.42 million. Artivion had a return on equity of 7.43% and a net margin of 2.21%.The firm’s revenue for the quarter was up 19.2% compared to the same quarter last year. As a group, sell-side analysts forecast that Artivion, Inc. will post 0.37 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on AORT shares. Canaccord Genuity Group decreased their target price on shares of Artivion from $51.00 to $48.00 and set a “buy” rating for the company in a research note on Friday, February 13th. Needham & Company LLC reiterated a “buy” rating and issued a $58.00 price target on shares of Artivion in a research note on Monday, February 2nd. Wall Street Zen downgraded shares of Artivion from a “buy” rating to a “hold” rating in a research report on Saturday, February 14th. Oppenheimer restated an “outperform” rating and set a $50.00 price objective on shares of Artivion in a research note on Friday, November 7th. Finally, Weiss Ratings raised shares of Artivion from a “sell (d)” rating to a “hold (c-)” rating in a report on Friday, February 20th. Six analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $50.47.

Hedge Funds Weigh In On Artivion

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Caitong International Asset Management Co. Ltd bought a new position in Artivion during the third quarter worth $27,000. Aster Capital Management DIFC Ltd raised its position in shares of Artivion by 402.3% in the third quarter. Aster Capital Management DIFC Ltd now owns 648 shares of the company’s stock valued at $27,000 after purchasing an additional 519 shares during the period. Larson Financial Group LLC lifted its stake in shares of Artivion by 148.5% during the 4th quarter. Larson Financial Group LLC now owns 942 shares of the company’s stock worth $43,000 after buying an additional 563 shares during the last quarter. USA Financial Formulas lifted its stake in shares of Artivion by 163.5% during the 4th quarter. USA Financial Formulas now owns 1,133 shares of the company’s stock worth $52,000 after buying an additional 703 shares during the last quarter. Finally, KBC Group NV bought a new stake in shares of Artivion during the 4th quarter worth about $65,000. 86.37% of the stock is owned by institutional investors.

About Artivion

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.